GlassScriptPhysician profile
Khoa D Tran
NPI 1427013986
$8,416.16
in general payments reported to CMS, 2019-2025
20 companies · $1,796 in 2025
The $1,796 reported for 2025 was more than what 88% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,888 · 2020: $642 · 2021: $1,296 · 2022: $990 · 2023: $639 · 2024: $1,165 · 2025: $1,796.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,489 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,488.61 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $2,111.40 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $1,479.70 | 2019-2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $776.89 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Abbvie INC. | $551.68 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $545.04 | 2024-2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $482.28 | 2020-2024 | Caplyta |
| Allergan, INC. | $450.76 | 2019-2020 | |
| Axsome Therapeutics, INC. | $410.73 | 2022-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $297.94 | 2019-2024 | Ingrezza |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $241.11 | 2022-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $237.00 | 2020-2025 | Capvaxive |
| Janssen Pharmaceuticals, INC | $221.33 | 2019-2025 | Invega Sustenna |
| Vanda Pharmaceuticals INC. | $135.64 | 2019-2024 | Fanapt |
| Tempus Ai, INC | $134.53 | 2024 | |
| Braeburn INC. | $100.05 | 2025 | Brixadi |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $94.84 | 2022 | |
| Lundbeck LLC | $50.82 | 2020-2021 | |
| Indivior INC. | $40.53 | 2019-2023 | Perseris |
| Sunovion Pharmaceuticals INC. | $36.37 | 2019 | |
| Nestle Healthcare Nutrition INC. | $17.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khoa Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.